Compass Therapeutics, Inc. (CMPX)
Largest Insider Buys in Sector
CMPX Stock Price History Chart
CMPX Stock Performance
About Compass Therapeutics, Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product …
Insider Activity of Compass Therapeutics, Inc.
Over the last 12 months, insiders at Compass Therapeutics, Inc. have bought $0 and sold $0 worth of Compass Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Compass Therapeutics, Inc. have bought $14.88M and sold $103,708 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $33,700 was made by Schuetz Thomas J. (CHIEF EXECUTIVE OFFICER) on 2023‑03‑10.
List of Insider Buy and Sell Transactions, Compass Therapeutics, Inc.
| 2023-03-10 | CHIEF EXECUTIVE OFFICER | 10,000 0.008% | $3.37 | $33,700 | -31.63% | |||
| 2023-02-27 | CHIEF EXECUTIVE OFFICER | 20,000 0.016% | $3.98 | $79,600 | -39.44% | |||
| 2023-02-15 | CHIEF EXECUTIVE OFFICER | 20,000 0.0153% | $3.86 | $77,200 | -38.82% | |||
| 2023-01-31 | CHIEF EXECUTIVE OFFICER | 20,000 0.016% | $4.05 | $81,000 | -35.38% | |||
| 2023-01-24 | CHIEF EXECUTIVE OFFICER | 20,000 0.0158% | $4.19 | $83,800 | -37.05% | |||
| 2022-11-25 | Sale | Chief Operating Officer | 2 <0.0001% | $4.36 | $9 | -28.83% | ||
| 2022-11-23 | Sale | Chief Operating Officer | 9,569 0.0088% | $4.30 | $41,147 | -29.89% | ||
| 2022-11-22 | Sale | Chief Operating Officer | 14,929 0.0139% | $4.19 | $62,553 | -27.27% | ||
| 2022-11-08 | director | 402,000 0.2887% | $3.21 | $1.29M | -25.18% | |||
| 2022-11-08 | director | 402,000 0.2887% | $3.21 | $1.29M | -25.18% | |||
| 2022-09-07 | CHIEF EXECUTIVE OFFICER | 15,000 0.0148% | $3.03 | $45,450 | +4.92% | |||
| 2022-09-01 | CHIEF EXECUTIVE OFFICER | 15,000 0.0145% | $2.83 | $42,450 | +10.34% | |||
| 2022-08-17 | CHIEF EXECUTIVE OFFICER | 15,000 0.0151% | $3.05 | $45,750 | +6.67% | |||
| 2022-08-10 | CHIEF EXECUTIVE OFFICER | 15,000 0.0146% | $2.64 | $39,600 | +19.40% | |||
| 2022-08-01 | CHIEF EXECUTIVE OFFICER | 15,000 0.0145% | $2.58 | $38,700 | +21.21% | |||
| 2022-06-21 | CHIEF EXECUTIVE OFFICER | 20,000 0.019% | $2.80 | $56,000 | +9.25% | |||
| 2022-06-16 | CHIEF EXECUTIVE OFFICER | 20,000 0.0188% | $2.34 | $46,800 | +28.74% | |||
| 2022-06-13 | CHIEF EXECUTIVE OFFICER | 30,000 0.0339% | $2.29 | $68,700 | +57.71% | |||
| 2022-06-06 | CHIEF EXECUTIVE OFFICER | 30,000 0.0304% | $2.83 | $84,900 | +14.08% | |||
| 2022-06-01 | CHIEF EXECUTIVE OFFICER | 20,000 0.0206% | $3.03 | $60,600 | +8.22% |
Insider Historical Profitability
| ORBIMED ADVISORS LLC | director | 15219994 11.0619% | $1.38 | 3 | 0 | <0.0001% |
| GORDON CARL L | director | 15219994 11.0619% | $1.38 | 5 | 0 | +26.53% |
| OrbiMed Genesis GP LLC | 14690178 10.6769% | $1.38 | 2 | 0 | +76.65% | |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 6021873 4.3767% | $1.38 | 20 | 0 | +7.18% |
| Sunderland Julie | director | 2502025 1.8185% | $1.38 | 1 | 0 |
Institutional Investor Ownership
| OrbiMed | $44.28M | 16.25 | 22.36M | 0% | +$0 | 0.34 | |
| Adage Capital Partners Gp L L C | $22.04M | 8.09 | 11.13M | +12.65% | +$2.48M | 0.04 | |
| Janus Henderson | $12.82M | 4.72 | 6.49M | -0.83% | -$107,303.75 | 0.01 | |
| Blackstone | $12.26M | 4.5 | 6.19M | 0% | +$0 | 0.05 | |
| BlackRock | $11.94M | 4.38 | 6.03M | -3.05% | -$375,889.15 | <0.0001 |